Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Transplant ; 20(2): 241-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26750745

ABSTRACT

Cardiovascular diseases induce long-term morbidity and mortality of adult LT recipients. The aim of this retrospective study was to assess CVRF, lipid abnormalities, and atherosclerosis (appraised by c-IMT), more than 10 yr after pediatric LT. Thirty-one children who underwent LT between December 1990 and December 2000 were included. Median age at LT was 14 months (range 4-64), and median follow-up after LT was 11.9 yr (range 9.0-17.3). In our cohort, obesity (9.7%) and treated hypertension (9.7%) were rare. None of the patients was smoker or diabetic. High TC and TG were both observed in 6.5% of the patients. The mean c-IMT for male patients was 1.22 ± 1.55 and 1.58 ± 1.23 mm in female patients. Seven patients (22%) had a mean c-IMT above +2 s.d. Values below the 5th percentile were noted for LDL-cholesterol (58.1%), HDL-cholesterol (25.8%), apolipoprotein B (40%), and apolipoprotein A1 (20%). LDL-cholesterol and apolipoprotein B levels were significantly lower in patients treated by tacrolimus in comparison with CsA (p < 0.05). In conclusion, our results suggest that pediatric LT patients do not present significant CVRF; moreover, instead of hyperlipidemia, hypocholesterolemia (LDL-C) is frequent and immunosuppressive therapy is probably the cause.


Subject(s)
Cardiovascular Diseases/blood , Liver Failure/blood , Liver Transplantation , Adolescent , Apolipoprotein A-I/blood , Apolipoproteins B/blood , Biopsy , Cardiovascular Diseases/complications , Child , Child, Preschool , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cyclosporine/therapeutic use , Dyslipidemias/complications , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/therapeutic use , Infant , Liver/pathology , Liver Failure/complications , Liver Failure/surgery , Male , Retrospective Studies , Risk Factors , Tacrolimus/therapeutic use , Transplant Recipients , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...